Your browser doesn't support javascript.
loading
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.
de Jonge, A Vera; Duetz, Carolien; Bruins, Wassilis S C; Korst, Charlotte L B M; Rentenaar, Rosa; Cosovic, Meliha; Eken, Merve; Twickler, Inoka; Nijland, Marcel; van der Poel, Marjolein W M; de Heer, Koen; Klerk, Clara P W; Strobbe, Leonie; Oosterveld, Margriet; Boersma, Rinske; Koene, Harry R; Roemer, Margaretha G M; van Werkhoven, Erik; Chamuleau, Martine E D; Mutis, Tuna.
Affiliation
  • de Jonge AV; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • Duetz C; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Bruins WSC; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • Korst CLBM; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Rentenaar R; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • Cosovic M; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Eken M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • Twickler I; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Nijland M; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • van der Poel MWM; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • de Heer K; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • Klerk CPW; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Strobbe L; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • Oosterveld M; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Boersma R; Department of Hematology, Amsterdam UMC Location Vrije Universiteit, Amsterdam, The Netherlands.
  • Koene HR; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands.
  • Roemer MGM; Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands.
  • van Werkhoven E; Division of Hematology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
  • Chamuleau MED; Department of Internal Medicine, Flevoziekenhuis, Almere, The Netherlands.
  • Mutis T; Department of Internal Medicine, Dijklanderziekenhuis, Hoorn, The Netherlands.
Blood Adv ; 8(5): 1094-1104, 2024 Mar 12.
Article in En | MEDLINE | ID: mdl-38191686
ABSTRACT
ABSTRACT Patients with high-grade B-cell lymphoma with MYC and BCL2 rearrangements (HGBL-MYC/BCL2) respond poorly to immunochemotherapy compared with patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS) without a MYC rearrangement. This suggests a negative impact of lymphoma-intrinsic MYC on the immune system. To investigate this, we compared circulating T cells and natural killer (NK) cells of patients with HGBL-MYC/BCL2 (n = 66), patients with DLBCL NOS (n = 53), and age-matched healthy donors (HDs; n = 16) by flow cytometry and performed proliferation, cytokine production, and cytotoxicity assays. Compared with HDs, both lymphoma subtypes displayed similar frequencies of CD8+ T cells but decreased CD4+ T cells. Regulatory T-cell (Treg) frequencies were reduced only in patients with DLBCL NOS. Activated (HLA-DR+/CD38+) T cells, PD-1+CD4+ T cells, and PD-1+Tregs were increased in both lymphoma subtypes, but PD-1+CD8+ T cells were increased only in HGBL-MYC/BCL2. Patients with DLBCL NOS, but not patients with HGBL-MYC/BCL2, exhibited higher frequencies of senescent T cells than HDs. Functional assays showed no overt differences between both lymphoma groups and HDs. Deeper analyses revealed that PD-1+ T cells of patients with HGBL-MYC/BCL2 were exhausted with impaired cytokine production and degranulation. Patients with DLBCL NOS, but not patients with HGBL-MYC/BCL2, exhibited higher frequencies of NK cells expressing inhibiting receptor NKG2A. Both lymphoma subtypes exhibited lower TIM-3+- and DNAM-1+-expressing NK cells. Although NK cells of patients with HGBL-MYC/BCL2 showed less degranulation, they were not defective in cytotoxicity. In conclusion, our results demonstrate an increased exhaustion in circulating T cells of patients with HGBL-MYC/BCL2. Nonetheless, the overall intact peripheral T-cell and NK-cell functions in these patients emphasize the importance of investigating potential immune evasion in the microenvironment of MYC-rearranged lymphomas.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Programmed Cell Death 1 Receptor Limits: Humans Language: En Journal: Blood Adv Year: 2024 Type: Article Affiliation country: Netherlands

Full text: 1 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Programmed Cell Death 1 Receptor Limits: Humans Language: En Journal: Blood Adv Year: 2024 Type: Article Affiliation country: Netherlands